arrow
R

Rachel Yoder

University of Kansas Medical Center
H指数:12
被引数:729

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Analysis of the Radiosensitivity Index (RSI) in Paired Pre- and Post-Neoadjuvant Therapy Triple-Negative Breast Cancer

配对新辅助治疗前后的三阴性乳腺癌中放射敏感性指数(RSI)的分析

2025-09-250
PRE
Stromal tumor infiltrating lymphocytes and TNBC-DX provide complementary prognostic information in triple-negative breast cancer

基质肿瘤浸润淋巴细胞和TNBC-DX在 triple-negative breast cancer 中提供互补的预后信息

2025-07-011
PRE
SMARCA2 compensation of SMARCA4 loss mediates adaptive resistance to neoadjuvant systemic therapy in triple-negative breast cancer: paired transcriptomic analysis of pre- and post-treatment samples from NeoSTOP and NeoPACT
2024-05-020
PRE
Tumor infiltrating lymphocyte stratification refines AJCC TNM staging based outcomes of early-stage triple negative breast cancer treated with neoadjuvant anthracycline-free, docetaxel and carboplatin chemotherapy
2024-05-020
PRE
Tumor-Infiltrating Lymphocytes Refine Outcomes in Triple-Negative Breast Cancer Treated with Anthracycline-Free Neoadjuvant Chemotherapy
2024-03-115
OA
Association of TNBC-DX scores with outcomes in triple-negative breast cancer (TNBC) treated with neoadjuvant pembrolizumab and chemotherapy: a correlative analysis from NeoPACT and NeoSTOP trials
2023-03-015
PRE
Impact of low versus negative estrogen/progesterone receptor status on clinico-pathologic characteristics and survival outcomes in HER2-negative breast cancer
2022-07-1131
OAAI
Clinical and Biomarker Results from Phase I/II Study of PI3K Inhibitor Alpelisib plus Nab-paclitaxel in HER2-Negative Metastatic Breast Cancer

PI3K抑制剂Alpelisib联合Nab-紫杉醇治疗HER2-Negative转移性乳腺癌的I/II期临床和生物标志物结果

2021-02-1844
OA
Randomized Phase II Trial of Anthracycline-free and Anthracycline-containing Neoadjuvant Carboplatin Chemotherapy Regimens in Stage I-III Triple-negative Breast Cancer (NeoSTOP)
2021-02-1568
OAAI